Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013)
Bristol Myers Squibb's (CELG-RI) quarterly Work In Process came in at $884.0 million in Q1 2013, up 22.61% year-over-year from $721.0 million in Q1 2012, and up 8.6% quarter-over-quarter from $814.0 million in Q4 2012.
Analysis
Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Work In Process for 4 consecutive years, with $884.0 million the latest figure, recorded in Q1 2013.
- On a quarterly basis, Work In Process rose 22.61% year-over-year to $884.0 million in Q1 2013; TTM through Mar 2013 was $884.0 million, a 22.61% increase from a year earlier, with the FY2012 full-year figure at $814.0 million, up 26.01% from the prior year.
- Work In Process was $884.0 million for Q1 2013 at Bristol Myers Squibb, up from $814.0 million in the prior quarter.
- Over five years, Work In Process peaked at $884.0 million in Q1 2013 and troughed at $608.0 million in Q4 2010.
- A 4-year average of $739.3 million and a median of $715.0 million in 2011 frame the typical range for Work In Process.
- The widest YoY moves for Work In Process: up 26.01% in 2012, down 4.49% in 2012.
- Over 4 years, Work In Process stood at $608.0 million in 2010, then rose by 6.25% to $646.0 million in 2011, then advanced by 26.01% to $814.0 million in 2012, then gained by 8.6% to $884.0 million in 2013.
- The last three Work In Process figures came in at $884.0 million (Q1 2013), $814.0 million (Q4 2012), and $868.0 million (Q3 2012), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.46 Bn | 621.70 Bn | 17.26 Bn |
| 2 | AbbVie | 447.01 Bn | 440.44 Bn | 12.70 Bn |
| 3 | Merck | 358.21 Bn | 351.07 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.54 Bn | 259.85 Bn | 11.24 Bn |
| 5 | Pfizer | 156.67 Bn | 144.97 Bn | 10.94 Bn |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.86 Bn | 42.86 Bn | - |
| 8 | Incyte | 24.60 Bn | 20.06 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2013 | 884.00 Mn |
| Dec 31, 2012 | 814.00 Mn |
| Sep 30, 2012 | 868.00 Mn |
| Jun 30, 2012 | 755.00 Mn |
| Mar 31, 2012 | 721.00 Mn |
| Dec 31, 2011 | 646.00 Mn |
| Sep 30, 2011 | 709.00 Mn |
| Jun 30, 2011 | 698.00 Mn |
| Mar 31, 2011 | 690.00 Mn |
| Dec 31, 2010 | 608.00 Mn |